Skip to main content
MyPeptideDosagesMyPeptideDosages
single20MG

Cartalax

20MG Protocol

Cartalax 20MG

Injection Freq.

Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance

Cycle Sched.

8–12 weeks; optional extension to 16 weeks

Reconstitution

3.0 mL BAC water

May support fibroblast/chondrocyte proliferation signals (Ki-67) in cell models
Sirtuin upregulation signals and reduced pro-apoptotic markers (p53/caspase-3) described
MMP-9 inhibition signals supporting extracellular-matrix homeostasis
Collagen-related cartilage integrity rationale (sequence-motif link)
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1–22,000 mcg (2.0 mg)30
2Weeks 3–43,000 mcg (3.0 mg)45
3Weeks 5–84,000 mcg (4.0 mg)60
4Weeks 9–125,000 mcg (5.0 mg)75

Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance

8–12 weeks; optional extension to 16 weeks

Cartalax (Ala–Glu–Asp) is presented as an ultrashort Khavinson-class bioregulatory peptide with proposed gene-regulatory activity at low concentrations. The protocol links Cartalax’s sequence to a motif found in type XI collagen, a structural protein relevant to cartilage integrity, and frames the peptide as a potential cartilage-support bioregulator. In preclinical fibroblast and chondrocyte culture studies summarized on the page, Cartalax is reported to increase Ki-67 (a proliferation marker) and to increase sirtuin (SIRT-1/SIRT-6) expression while reducing p53 and caspase-3 activity (pro-apoptotic signaling). The page also cites inhibition of MMP-9 synthesis, an enzyme associated with extracellular-matrix degradation, which is positioned as supportive of matrix homeostasis. Overall, Cartalax is framed as influencing cell survival, proliferation, and matrix-remodeling programs via epigenetic/gene-expression regulation; the protocol notes that large human RCT evidence is not available.
Mild injection-site reactions (redness/itching)
Limited evidence base (primarily in vitro/rodent data
no large human RCTs described)
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)

Related peptide protocols

More research-backed dosing guides in this category.